PT-141 / Bremelanotide research guide
Cyclic melanocortin receptor agonist
A guide that maps the research code PT-141 to bremelanotide while separating authorised pharmaceutical evidence from unrelated catalogue material.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
PT-141 is the development code associated with bremelanotide, a cyclic melanocortin receptor agonist derived from Melanotan II research. Similar ancestry does not make PT-141 and Melanotan II interchangeable. Exact identity, counter-ion, content and formulation remain batch-specific questions.
02 · Evidence position
What the literature can support
Large randomised phase 3 studies exist for a manufactured bremelanotide medicine in a narrowly defined population and indication. That is meaningful human evidence for that product, but it cannot be used to imply equivalence, approval or safety of a separately supplied research vial.
03 · Study-level map
Evidence and its limits
What late-stage evidence exists?
Two randomised, double-blind, placebo-controlled phase 3 trials evaluated a pharmaceutical bremelanotide product in premenopausal women with a defined diagnosis.
Limit: The results are product-, population- and indication-specific and do not validate a generic PT-141-labelled material.
Can PT-141 be inferred from a related name?
The literature distinguishes bremelanotide from Melanotan II despite their developmental relationship.
Limit: A vendor name or family resemblance is not a substitute for direct molecular identity testing.
04 · Analytical context
Questions a batch record should answer
- 01Does identity testing distinguish bremelanotide from Melanotan II and other melanocortin analogues?
- 02Are cyclic integrity, related peptides and degradation products addressed by complementary methods?
- 03Is quantitative peptide content reported separately from HPLC area purity?
05 · Boundary conditions
What this record does not establish
- Medicine evidence does not establish equivalence of an independent research material.
- The approved indication in another jurisdiction should not be broadened into general claims.
- This page does not provide sexual-health or administration advice.
Sources checked
- 1.Bremelanotide: two randomized phase 3 trials
PubMed / Obstetrics & Gynecology · 2019 · Primary study
- 2.Evaluation of Melanotan-II in a pilot phase-I clinical study
PubMed / Life Sciences · 1996 · Primary study